AbbVie Raises Outlook After Strong Q2, Eyes Acquisitions

AbbVie reported strong second-quarter 2025 results, exceeding expectations with $15.42 billion in revenue—a 6.6% year-over-year increase—and adjusted earnings per share of $2.97, driven by strong sales of Skyrizi, Rinvoq, and growth in the Botox and neurosciences segments. Although Humira sales declined significantly due to biosimilar competition, AbbVie raised its full-year adjusted EPS guidance to $11.88–$12.08. Recent acquisitions, including Capstan Therapeutics and possible talks to acquire Gilgamesh Pharmaceuticals, reflect ongoing investment in the company's pipeline. The company also improved its operating margin and cited positive regulatory progress and a supportive trade environment for its Irish-produced drugs. Management remains confident about momentum into the second half of the year, but long-term revenue growth trends remain modest. Foreign exchange rates were noted as a current headwind.